-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
Sunshine Biopharma Announces Share Repurchase Program
Sunshine Biopharma Announces Share Repurchase Program
MONTREAL, Jan. 19, 2023 (GLOBE NEWSWIRE) -- Sunshine Biopharma Inc. (NASDAQ: "SBFM"), a pharmaceutical company offering and researching life-saving medicines in a variety of therapeutic areas including oncology and antivirals today announced its board of directors has authorized a share repurchase program to acquire up to $2 million of the Company's common stock.
The Company may purchase common stock on the open market, through privately negotiated transactions, or otherwise, in compliance with the rules of the United States Securities and Exchange Commission and other applicable legal requirements. As of September 30, 2022, the Company had approximately $40.5 million of cash and cash equivalents. The Company had approximately 22.6 million shares of common stock issued and outstanding as of November 7, 2022.
Dr. Steve Slilaty, CEO of Sunshine Biopharma commented: "As we continue to make progress on our oncology and antiviral drug development pipeline and devote energy towards growing the sales and profitability of our recently acquired pharmaceutical company (Nora Pharma Inc.), we believe the current market environment and the Company's healthy balance sheet allow us to capture additional value for our shareholders through this measured buyback program."
The timing, number of shares repurchased and prices paid for the repurchased shares under this program will be at the discretion of management and will depend on market conditions as well as regulatory limitations, including blackout period restrictions. The repurchase program does not obligate the Company to acquire any particular amount of shares, and the repurchase program may be suspended or discontinued at any time at the Company's discretion.
Information regarding share repurchases will be provided in the Company's periodic reports on Form 10-Q and 10-K as the Company ordinarily files with the Securities and Exchange Commission or as may be required by applicable securities laws.
About Sunshine Biopharma Inc.
Sunshine Biopharma recently acquired Nora Pharma Inc. and as a result the Company now has 36 employees and 50 generic prescription drugs on the market in Canada. In parallel, Sunshine Biopharma is continuing its drug development R&D program. In addition to the K1.1 anticancer mRNA project, the Company is working on the development Adva-27a, a small molecule having the unique ability to destroy multidrug resistant cancer cells, including pancreatic cancer cells, small-cell lung cancer cells, breast cancer cells, and uterine sarcoma cells. Clinical trials for pancreatic cancer indication are planned to be conducted at McGill University's Jewish General Hospital in Montreal, Canada. Sunshine Biopharma is also engaged in the development of a COVID-19 treatment in collaboration with the University of Arizona. The project, currently in advanced stages of preclinical studies, is focused on the development of an inhibitor for SARS-CoV-2 PLpro protease. PLpro is unique to the SARS group of Coronaviruses and is responsible for suppressing the human immune system making this group of viruses more deadly. For more information, please visit:
Safe Harbor Forward-Looking Statements
This press release contains forward-looking statements which are based on current expectations, forecasts, and assumptions of Sunshine Biopharma, Inc. (the "Company") that involve risks as well as uncertainties that could cause actual outcomes and results to differ materially from those anticipated or expected. These statements appear in this release and include all statements that are not statements of historical fact regarding the intent, belief or current expectations of the Company, including statements related to the Company's drug development activities, financial performance, and future growth. These risks and uncertainties are further described in filings and reports by the Company with the U.S. Securities and Exchange Commission (SEC). Actual results and the timing of certain events could differ materially from those projected in or contemplated by the forward-looking statements due to a number of factors detailed from time to time in the Company's filings with the SEC. Reference is hereby made to cautionary statements and risk factors set forth in the Company's most recent SEC filings.
For Additional Information:
Sunshine Biopharma Contact:
Camille Sebaaly, CFO
Direct Line: 514-814-0464
camille.sebaaly@sunshinebiopharma.com
Sunshine Biopharma Media Contact:
Christine Petraglia
TraDigital IR
Direct Line: 917-633-8980
investors@sunshinebiopharma.com
蒙特利尔,2023年1月19日(环球网)--阳光生物制药公司(纳斯达克代码:“SBFM”),一家在肿瘤和抗病毒药物等多种治疗领域提供和研究救命药物的制药公司今天宣布,其董事会已批准一项股票回购计划,以收购高达200万美元的公司普通股。
根据美国证券交易委员会的规则和其他适用的法律要求,公司可以在公开市场上、通过私下协商的交易或其他方式购买普通股。截至2022年9月30日,该公司拥有约4050万美元的现金和现金等价物。截至2022年11月7日,该公司已发行和流通的普通股约为2260万股。
阳光生物制药公司首席执行官史蒂夫·斯莱拉蒂博士评论说:“随着我们继续在我们的肿瘤学和抗病毒药物开发流水线上取得进展,并致力于增加我们最近收购的制药公司(Nora Pharma Inc.)的销售和盈利能力,我们相信,目前的市场环境和公司健康的资产负债表使我们能够通过这一有节制的回购计划为我们的股东获取额外价值。”
根据该计划,回购股份的时间、数量和支付的价格将由管理层酌情决定,并将取决于市场状况以及监管限制,包括禁售期限制。回购计划并不要求本公司购买任何特定数量的股份,本公司可随时酌情暂停或终止该回购计划。
有关股份回购的信息将在公司通常向证券交易委员会提交的10-Q和10-K表格的定期报告中提供,或根据适用的证券法的要求提供。
阳光生物医药公司简介
阳光生物制药公司最近收购了Nora Pharma Inc.,因此,该公司目前在加拿大市场上有36名员工和50种非专利处方药。与此同时,阳光生物医药公司正在继续其药物开发研发计划。除了K1.1抗癌基因项目外,该公司还致力于开发Adva-27A,这是一种具有独特能力的小分子,可以摧毁多药耐药癌细胞,包括胰腺癌细胞、小细胞肺癌细胞、乳腺癌细胞和子宫肉瘤细胞。胰腺癌适应症的临床试验计划在加拿大蒙特利尔的麦吉尔大学犹太综合医院进行。阳光生物制药公司还与亚利桑那大学合作,参与了新冠肺炎疗法的开发。该项目目前处于临床前研究的后期阶段,重点是开发一种SARS-CoV-2 PLPro蛋白酶的抑制剂。PLPro是SARS冠状病毒组所特有的,负责抑制人类免疫系统,使这组病毒更致命。如需更多信息,请访问:
安全港前瞻性陈述
本新闻稿包含前瞻性陈述,这些陈述基于阳光生物医药公司(“本公司”)目前的预期、预测和假设。这些前瞻性陈述涉及风险和不确定因素,可能导致实际结果和结果与预期或预期的大不相同。这些陈述出现在本新闻稿中,包括所有与公司的意图、信念或当前预期有关的非历史事实陈述,包括与公司的药物开发活动、财务业绩和未来增长有关的陈述。这些风险和不确定性在该公司提交给美国证券交易委员会(美国证券交易委员会)的文件和报告中有进一步的描述。某些事件的实际结果和时间可能与前瞻性陈述中预测的或预期的大不相同,原因是公司在提交给美国证券交易委员会的文件中不时详述的一些因素。兹参考本公司最近提交给美国证券交易委员会的文件中的警告性声明和风险因素。
有关其他信息,请访问:
阳光Biophma联系方式:
首席财务官卡米尔·塞巴利
直拨电话:514-814-0464
邮箱:camille.sebaaly@sunshinebiopharma.com
阳光Biophma媒体联系人:
克里斯汀·佩特拉格里亚
曲吉红外线
直拨电话:917-633-8980
邮箱:Investors@sunshinebiopharma.com
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧